FOR IMMEDIATE RELEASE |
CONTACT:
|
June 27, 2003 |
Kate Dwyer: 202-226-7326
|
Ryan
Votes for Landmark Legislation to Update, Fortify Medicare for Future; Give
Seniors Choice, Access to Rx Drug Benefit
WASHINGTON
– Today the U.S. House of Representatives voted 216-215 to pass H.R. 1, the
Medicare Prescription Drug and Modernization Act of 2003.
Wisconsin’s First District Congressman Paul Ryan, who serves on the
House Ways and Means Committee, helped shape and pass this legislation, which
makes a prescription drug benefit available to Medicare beneficiaries who want
it and includes key structural reforms aimed at strengthening Medicare for
future generations. Ryan voted in
favor of the bill’s passage.
In
addition to prescription drug coverage and long-overdue modernization, the
measure helps secure fairer Medicare benefits for Wisconsin and contains a
provision Ryan worked on that would reduce the risk of medication errors by
moving forward with electronic prescribing (e-prescribing).
“It
was crucial that we pass this Medicare legislation, not only because seniors
have waited long enough for a prescription drug benefit but also because it is
forward-looking,” Ryan said. “Our
plan recognizes that Medicare is in trouble financially and that real structural
improvements are needed to help the program handle the retirement of the baby
boom generation and uphold its promise to both current and future generations of
seniors. These reforms are
critical. Without them, the new
benefits would accelerate Medicare’s insolvency which is currently only 10
years away.”
“This
measure sets Medicare on the right track,” Ryan said. “It brings the program up to date with the option of
prescription drug coverage, competition to hold down costs and give seniors the
chance to choose the best plan for them, and e-prescribing to reduce medication
mistakes. It also helps
equalize reimbursement rates for Wisconsin hospitals and doctors with the rest
of the country.”
“I
will be working to make sure these provisions are not watered down or taken out
of the final legislation during conference negotiations, when differences
between the House and Senate versions are addressed,” Ryan said.
H.R.
1 includes the following provisions:
Prescription Drug Benefit
- Fully subsidized premium and cost-sharing up to 135% of poverty, phasing out at 150% of poverty.
- High-income beneficiaries have a higher catastrophic benefit.
Medicare Modernizations to Strengthen the Program for
the Future, Ensure Choices for Seniors
Revitalizes Medicare + Choice, renaming it Medicare Advantage.
Clears path for creation of the President’s Enhanced Fee-for-Service (FFS) and Preferred Provider (PPO) plans to make more options available to seniors, alongside traditional fee-for-service Medicare and Medicare Advantage plans.
Initiates FEHBP-style competitive reforms in 2010. This would enable seniors to select the plan that best meets their needs, similar to the way federal employees currently choose from a range of plans through the Federal Employees Health Benefit Program (FEHBP). This entitles seniors to the same health care Members of Congress have.
Help for Wisconsin Hospitals, Doctors
Strengthens rural health care, delivering relief for underpaid rural and small urban hospitals and doctors.
Improves reimbursement policy, narrowing the regional disparity in reimbursements to hospitals.
Reforms irrational physician payments, helping to prevent doctors from leaving Medicare.
Provides regulatory relief for doctors and hospitals.
Includes reform to help providers better understand Medicare’s program rules and regulations.
Other Key Improvements to Enhance Seniors’ Health
Covers an initial physical, cholesterol screening, and colorectal cancer tests.
Puts a one-year moratorium on the implementation of a $1500 physical therapy cap.
Calls for electronic prescribing – a provision Ryan helped craft – to reduce prescription error, make seniors’ drug regimens safer.
Pharmacy therapy and chronic care management for beneficiaries with chronic conditions.
Codifies regulations that would speed the approval of generic drugs by limiting the time that brand-name pharmaceutical companies can stay their patents in court.